United Therapeutics (NASDAQ:UTHR) CFO Sells $5,729,400.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $572.94, for a total transaction of $5,729,400.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,814,815.44. This represents a 34.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

James Edgemond also recently made the following trade(s):

• On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $565.63, for a total transaction of $5,656,300.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $564.11, for a total transaction of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $567.31, for a total transaction of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.47, for a total transaction of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $573.03, for a total transaction of $5,730,300.00.
• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.58, for a total transaction of $5,785,800.00.
• On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $576.93, for a total transaction of $5,769,300.00.
• On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.61, for a total transaction of $5,726,100.00.
• On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $568.83, for a total transaction of $5,688,300.00.
• On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The stock was sold at an average price of $575.85, for a total transaction of $209,609.40.

United Therapeutics Stock Down 0.9%

UTHR opened at $556.82 on Friday. The company has a market capitalization of $23.64 billion, a price-to-earnings ratio of 20.55, a PEG ratio of 1.83 and a beta of 0.60. The firm has a 50-day moving average price of $566.51 and a 200-day moving average price of $515.84. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.63 EPS. On average, sell-side analysts expect that United Therapeutics Corporation will post 26.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on UTHR. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Royal Bank Of Canada reduced their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Bank of America lifted their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Cantor Fitzgerald lifted their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Finally, UBS Group lifted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $619.42.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently bought and sold shares of UTHR. Geneos Wealth Management Inc. grew its stake in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 70 shares in the last quarter. Jump Financial LLC purchased a new position in United Therapeutics during the second quarter valued at approximately $277,000. Cerity Partners LLC grew its stake in United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after acquiring an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia grew its stake in United Therapeutics by 6.9% during the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics is still drawing support from bullish analyst coverage, including recent higher price targets and buy/overweight ratings, which suggests Wall Street remains constructive on the long-term outlook.
• Positive Sentiment: The company continues to highlight clinical and business-development catalysts, including its PHINDER screening study, xenokidney/EXTEND trial progress, and a planned presentation at the Jefferies Global Healthcare Conference, all of which help keep the growth story visible to investors. Article Title Article Title
• Neutral Sentiment: A separate article referenced United Therapeutics in a broader mid-cap stock discussion, but it did not appear to contain company-specific new information likely to move the stock.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares and CFO James Edgemond sold 10,000 shares this week. Multiple insider sales can weigh on sentiment, especially when they come soon after a disappointing earnings report. Article Title Article Title
• Negative Sentiment: The company’s most recent quarterly results missed estimates on both EPS and revenue, leaving investors with an ongoing fundamental overhang despite strong profitability metrics.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.